Application of CD177 as biomarker for detecting acute myocardial infarction

Abstract

The invention provides application of CD177 as a biomarker for detecting acute myocardial infarction, and relates to the technical field of biomedicine. The application can be used for predicting the attack of the acute myocardial infarction before the attack of the acute myocardial infarction to achieve the purpose of nipping in the bud, so that medical staff can better implement medical measures, the probability of sudden death of a patient due to the acute myocardial infarction is reduced The biomarker for detecting the acute myocardial infarction comprises CD177 protein and CD177 positive neutrophils, and the expression condition of the CD177 in a human body is used as a basis for judging the acute myocardial infarction. Compared with the original methods for detecting cardiac troponin T (cTnI), creatine kinase-MB (CK-MB) and the like as pathogenesis indexes of the acute myocardial infarction, the application has the advantages that the pathogenesis of the acute myocardial infarction can be predicted in advance, and a research direction is provided for predicting the pathogenesis time of the acute myocardial infarction in the future.

Description

technical field [0001] The invention relates to the field of biomedical technology, in particular to the use of CD177 as a biomarker for detecting acute myocardial infarction. Background technique [0002] Acute myocardial infarction (AMI) refers to acute ischemic necrosis of the myocardium caused by sudden occlusion of the coronary arteries. Morbidity and fatality rates have remained high in both developed and developing countries. At present, the prevalence and mortality of cardiovascular diseases in my country are still on the rise, and the burden of cardiovascular diseases is increasing day by day, which has become a major public health problem, especially in recent years, the trend of younger age of onset has become increasingly obvious. According to data released by the National Health and Medical Commission, from 2007 to 2019, the incidence of acute myocardial infarction among people over the age of 25 has increased year by year, especially the incidence of people ag...

AI Technical Summary

Problems solved by technology

[0003] At present, serum myocardial injury markers such as creatine kinase isoenzyme (CK-MB), myoglobin, cardiac troponin T (cTnI), troponin T (TnT), and brain natriuretic peptide (BNP) are usually used clinically. The increase of the level and the change of electrocardiogram are used as the basis for the diagnosis of acute myocardial infarction. However, the changes of these indicators occur after the onset of the disease, and cannot play an early role in preventing the occurrence of the disease.

Images